All In Biotech

Drug Trial Radar · NCT00423657

Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections

A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin and Skin Structure Infection (cSSSI)

Last checked: Nov 19, 2026Latest source record: Mar 14, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 680 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

680

Actual

Start

Mar 2007

Primary completion

Dec 2007

Study completion Dec 2007

Sponsor

Lead sponsor
Forest LaboratoriesAbbVie (ABBV)
Sponsor type
Industry
First posted
Jan 18, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether ceftaroline is effective and safe in the treatment of complicated skin infections in adults.

Conditions

  • Bacterial Infections

Interventions

  • ceftarolineDrug

    600 mg parenteral infused over 60 minutes, every 12 hours for 5 to 14 days

  • vancomycin plus aztreonamDrug

    vancomycin at 1 g parenteral infused over 60 minutes followed by aztreonam 1 g infused over 60 minutes, every 12 hours, for 5 to 14 days.

  • PlaceboDrug

    Ceftaroline fosamil 600 mg administered intravenously over 60 minutes every 12 hours, followed by placebo administered over 60 minutes every 12 hours.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Cure Rate at Test of Cure (TOC) (MITT Population)Time frame: 8-15 days after last dose of study drug administration
  2. The Primary Efficacy Outcome Measure Was the Per-subject Clinical Cure Rate at the TOC Visit in the Clinically Evaluable (CE) Populations.Time frame: 8-15 days after last dose of study drug

Locations

54 sites in 12 countries. Site status is shown where the registry gives one.

  • Investigational Site

    Buena Park, California

  • Investigational Site

    Hawaiian Gardens, California

  • Investigational Site

    Los Angeles, California

  • Investigational Site

    Pasadena, California

  • Investigational Site

    San Diego, California

  • Investigational Site

    San Jose, California

  • Investigational Site

    Atlantis, Florida

  • Investigational Site

    Columbus, Georgia

  • Investigational Site

    Marietta, Georgia

  • Investigational Site

    Springfield, Illinois

  • Investigational Site

    Baltimore, Maryland

  • Investigational Site

    Minneapolis, Minnesota

  • Investigational Site

    Butte, Montana

  • Investigational Site

    Somers Point, New Jersey

  • Investigational Site

    Toledo, Ohio

  • Investigational Site

    Tacoma, Washington

  • Investigational Site

    Milwaukee, Wisconsin

  • Investigational Site

    Buenos Aires, Argentina

  • Investigational Site

    Córdoba, Argentina

  • Investigational Site

    Santa Fe, Argentina

  • Investigational Site

    Braunau am Inn, Austria

  • Investigational Site

    Graz, Austria

  • Investigational Site

    Sankt Pölten, Austria

  • Investigational Site

    Sao Paula, Brazil

  • Investigational Site

    Temuco, Chile

  • Investigational Site

    Valdivia, Chile

  • Investigational Site

    Cottbus, Germany

  • Investigational Site

    Dortmund, Germany

  • Investigational Site

    Homburg/Saar, Germany

  • Investigational Site

    Mainz, Germany

  • Investigational Site

    Wiesbaden, Germany

  • Investigational Site

    Riga, Latvia

  • Investigational Site

    Guadalajara, Jalisco, Mexico

  • Investigational Site

    Seattle Zapopan, Jalisco, Mexico

  • Investigational Site

    Bielsko-Biala, Poland

  • Investigational Site

    Krakow, Poland

  • Investigational Site

    Krakow, Poland

  • Investigational Site

    Lodz, Poland

  • Investigational Site

    Lublin, Poland

  • Investigational Site

    Poznan, Poland

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.